Clinical Trial Update: GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of GEN1046 in combination with anticancer agents for advanced endometrial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• GEN1046

Snippet

Sponsor: Genmab | Conditions: Advanced Endometrial Cancer | Phase 2 | Status: WITHDRAWN